The Latest Breaking News from Pfizer

Pfizer Inc. said it launched a study of its oral Covid-19 treatment among children age 6 and up who have been infected by the virus and are at risk of progressing to severe disease.

Pfizer Inc (NYSE: PFE) has initiated a Phase 2/3 EPIC-PEDS trial to evaluate Paxlovid (nirmatrelvir and ritonavir tablets) 

Vaccine stocks popped Wednesday, but remain broadly under pressure. Their Covid wares are predicted to fall as the virus becomes endemic.

Here's a roundup of top developments in the biotech space over the last 24 hours.

‘Jared didn’t budge. In his mind, America was coming first no matter what,’ Albert Bourla writes

More research is needed, but likely omicron is to blame and not an overly low dosage for children

A whale with a lot of money to spend has taken a noticeably bullish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 27 strange trades.

About 100,000 doses of Pfizer's COVID-19 vaccine are at risk of being destroyed by the end of this month due to slow uptake by citizens, South African health authorities said on Friday.

Pfizer Inc (NYSE:PFE) is expected to provide around 10 million courses of its highly effective COVID-19 antiviral treatment Paxlovid to low- and middle-income countries in 2022, reports Reuters citing an official with the Global Fund. The Fund's head of strategy for policy, Harley Feldbaum, said Pfizer had committed at least that many…

The European Medicines Agency said it has authorized Moderna’s coronavirus vaccine for children aged six to 11, in addition to recommending booster shots of Pfizer’s vaccine for those aged 12 and over

Pfizer Inc (NYSE: PFE) is trading higher Wednesday after the company received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for PF-06482077, or RSVpreF, the company's respiratory syncytial virus vaccine candidate.